urokinase

Conclusions: Intravenous urokinase thrombolysis could an effective and safe treatment for acute cerebral infarction.

结论: 尿激酶静脉溶栓治疗急性脑梗死有效且相对安全.

D-dimer; lower extremity deep venous thrombosis; thrombolytic therapy; urokinase.

D - 二聚体; 下肢深静脉血栓形成; 溶栓治疗; 尿激酶.

Objective: To identify of urokinase-type plasminogen activator ( UPA ) expression in patients with epithelial ovarian carcinoma.

目的: 探讨尿激酶型纤溶酶原激活因子 ( UPA ) 的蛋白表达与上皮性卵巢癌生物学行为的关系.

Subconjunctival injection urokinase combined with dexamethasone was performed 2-3 times.

药物治疗行尿激酶联合地塞米松结膜下注射,共2~次.

Objective To discuss the clinical effect on ventricular hemorrhage by lateral ventricular exporting and infusing Urokinase.

目的探讨侧脑室引流术及注入尿激酶治疗脑室出血的临床疗效.

Methods All 82 patients received intravenous urokinase ( UK ) for acute ischemic stroke.

方法　82例急性脑梗死患者接受尿激酶 ( UK ) 静脉溶栓治疗.

Thrombolytic therapy of acute MVT with Urokinase and Batroxobin is feasible, effective and safe.

尿激酶联合巴曲酶治疗MVT是有效和安全的.

In this process, urokinase-type plasminogen activator ( uPA ) and P-selectin play a very important role.

在此过程中, 尿激酶型纤溶酶原激活物(urokinase -type plasminogenactivator,uPA ) 和P - 选择素起着十分重要的作用.

Methods: Non-glycosylated pro-urokinase was created by Asn 302-Ala 302 mutagenesis.

方法: 将302位天冬酰胺(Asn302)突变为丙氨酸(Ala302 ),构建非糖基化尿激酶原.